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A B S T R A C T
Background
Severe malaria results in over a million deaths every year, most of them in children aged under five years and living in sub-Saharan
Africa. This review examines whether treatment with artesunate, instead of the standard treatment quinine, would result in fewer deaths
and better treatment outcomes.
Objectives
To compare artesunate with quinine for treating severe malaria.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE,
LILACS, ISI Web of Science, the metaRegister of Controlled trials (mRCT), conference proceedings, and reference lists of articles to
November 2010.
Selection criteria
Randomized controlled trials comparing intravenous, intramuscular, or rectal artesunate with intravenous or intramuscular quinine for
treating adults and children with severe malaria who are unable to take medication by mouth.
Data collection and analysis
Two authors independently assessed the eligibility and risk of bias of trials, and extracted and analysed data. The primary outcome was
all-cause death. Dichotomous outcomes were summarized using risk ratios (RR) and continuous outcomes by mean differences (MD).
Where appropriate, we combined data in meta-analyses.
Main results
Eight trials enrolling 1664 adults and 5765 children are included in this review.
Treatment with artesunate significantly reduced the risk of death both in adults (RR 0.61, 95% Confidence Interval (CI) 0.50 to 0.75;
1664 participants, five trials) and children (RR 0.76, 95% CI 0.65 to 0.90; 5765 participants, four trials)
In children, treatment with artesunate increased the incidence of neurological sequelae at the time of hospital discharge. The majority
of these sequelae were transient and no significant difference between treatments was seen at later follow up.
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Authors’ conclusions
The evidence clearly supports the superiority of parenteral artesunate over quinine for the treatment of severe malaria in both adults
and children and in different regions of the world.
P L A I N L A N G U A G E S U M M A R Y
Artesunate reduces death from severe malaria
Severe malaria occurs when infection with the malaria parasite is complicated by serious failure of the body’s major organs, and results
in over a million deaths every year. Sometimes severe malaria is associated with coma and is known as cerebral malaria. Following
cerebral malaria a small proportion of children suffer with long-term neurological disability.
This review of trials assessed the effectiveness of artesunate compared with the standard treatment quinine. Eight trials involving 1664
adults and 5765 children were identified, from study sites in Asia and Africa.
Treating adults in Asia with artesunate instead of quinine would prevent an extra 94 deaths for every 1000 patients treated. In trials
involving children, the proportion of deaths was lower than in the trials involving adults. This lower risk of death results in a smaller
benefit in children than in adults, but would still save an extra 26 lives for every 1000 children treated.
In the children who survived their illness, there were more neurological problems at the time of hospital discharge in those treated
with artesunate than those treated with quinine. However, the majority of these neurological problems had resolved when they were
reviewed 28 days later, and at this timepoint there was no difference between the two treatment groups.
Artesunate should be the drug of choice for adults and children with severe malaria worldwide.
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B A C K G R O U N D
Description of the condition
Malaria is a febrile illness caused by infection with the Plasmodium
parasite, which is transmitted fromperson to person bymosquitos.
Five species of plasmodium are known to cause disease in humans:
P. falciparum, P. vivax, P. ovale, P. malariae, and P knowlesi (WHO
2010). P. falciparum is the most common malaria parasite world-
wide, and is responsible for almost all of the severe disease and
deaths (WHO 2000; WHO 2008).
Repeated exposure to malaria infection over 5 to 10 years can pro-
duce a naturally acquired immunity in humans, which is protec-
tive against the most severe forms of the disease (Doolan 2009).
Consequently, in high transmission settings as seen in large parts
of Africa, young children are most at risk prior to the acquisition
of effective immunity, whereas in low transmission settings, or in
travellers from non-endemic areas, adults are often equally vulner-
able to severe disease (WHO 2000).
Severe malaria is diagnosed on the basis of a positive blood slide or
antigen test for malaria, plus the presence of clinical or laboratory
markers which indicate vital organ dysfunction. These markers
include impaired consciousness, coma, convulsions, respiratory
distress, shock (systolic blood pressure < 70 mmHg in adults,
< 50 mmHg in children), jaundice, haemoglobinuria, or severe
acidosis or anaemia (WHO 2010). Cerebral malaria is a specific
type of severe malaria characterised by an unrousable coma. Even
with correct treatment cerebral malaria can have a mortality rate
approaching 20%, and persistent neurological sequelae are seen in
a small proportion of survivors (Jaffar 1997).
The standard treatment for severe malaria has been an intravenous
infusion or intramuscular injection of quinine (WHO 2000). A
loading dose of 20 mg/kg is recommended to reduce the time
needed to reach effective concentrations in the blood, with subse-
quent dosing at 10 mg/kg at eight hourly intervals (White 1983b;
van Der Torn 1996). A Cochrane Review found a significant re-
duction in fever clearance time and parasite clearance time with a
loading dose compared with no loading dose but concluded that
data were insufficient to demonstrate an impact on mortality (Lesi
2004).
Adverse effects resulting from quinine therapy are common. Cin-
chonism (symptoms of quinine overdose) often occurs with con-
ventional dose regimens. This usually mild and reversible symp-
tom complex consists of tinnitus, deafness, dizziness, and vomit-
ing, and may affect adherence (Alkadi 2007). Hypoglycaemia is a
less common but more serious adverse effect (White 1983). Toxic
levels of quinine can occur following rapid intravenous admin-
istration and can result in heart rhythm disturbances, blindness,
coma, and even death (Alkadi 2007). In addition, there is limited
evidence that the efficacy of quinine in severe malaria may be de-
clining in some parts of South-East Asia (Wongsrichanalai 2002).
Description of the intervention
Artesunate is one of a number of antimalarials derived from
artemisinin, the active ingredient in a Chinese herbal remedy for
fever, Artemesia annua. The artemisinin derivatives are now the
recommended treatment for uncomplicated (less severe) malaria,
when they are given orally in combination with a partner drug,
as Artemisinin-based Combination Therapy (ACT), to delay or
prevent the development of artemisinin resistance (WHO 2010).
The artemisinin derivatives are generally regarded as safe in hu-
mans (Ribeiro 1998; Alkadi 2007; Nosten 2007). Animal stud-
ies using very high doses of artemisinins have demonstrated fo-
cal brain stem lesions particularly affecting the auditory pathways
(Brewer 1994; Nontprasert 1998; Genovese 2000; Nontprasert
2000; Nontprasert 2002), but studies of brain stem function in
humans, including audiometry, have failed to show any abnor-
mality following repeated courses (Ribeiro 1998; Kissinger 2000).
To date, only one nested case-control study has demonstrated
a significant audiometric hearing loss in factory workers treated
with artemether-lumefantrine for uncomplicated malaria com-
pared with workers with no history of exposure to malaria infec-
tion or artemether-lumefantrine (Toovey 2004). This result needs
to be interpreted with caution due to a number of design limita-
tions.
How the intervention might work
Deaths from severe malaria often occur during the first 24 to 48
hours following hospital admission. Consequently, to be effective
antimalarial drugs need to achieve rapid therapeutic blood con-
centrations following administration.
Compared to quinine, the artemisinin derivatives have been shown
to clear malaria parasites from the blood faster, and to have a
broader spectrum of activity (ter Kuile 1993; Adjuik 2004). Im-
portantly they are effective against young ring forms of the parasite
before they sequester in the microcirculation of vital organs, a ma-
jor pathophysiological step in the development of severe disease
(ter Kuile 1993; WHO 2000).
Artesunate is the most studied artemisinin-derivative for the treat-
ment of severemalaria andmay be given by intramuscular or intra-
venous injection. It has been shown to reliably reach peak concen-
trations within one hour of administration (Nealon 2002; Hien
2004).
Of the alternatives, artemether and arteether are available as oil-
based, intramuscular formulations. Artemether is prone to erratic
and partial absorption (Karbwang 1997;Murphy 1997;Mithwani
2003), and arteether to low peak concentrations and slow ab-
sorption (Looareesuwan 2002; Li 2004). Systematic reviews of
artemether and arteether compared to quinine have so far failed
to show a reduction in mortality compared to quinine therapy,
although the data are limited (AQMSG 2001; Afolabi 2004; Kyu
2009).
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Why it is important to do this review
A Cochrane Review prepared in year 2000 assessed the effects of
the artemisinin derivatives, including artesunate, for treating se-
vere malaria (McIntosh 2000). This review has since been super-
seded by a series of Cochrane Reviews examining the different
artemisinin derivatives.
This review was first published in 2006 and demonstrated the
superiority of artesunate for treating adults in Asia, but found
insufficient data tomake firm conclusions in children. This update
includes two additional, recently completed trials, focusing on
artesunate versus quinine in African children.
O B J E C T I V E S
To compare artesunate with quinine for treating severe malaria.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials.
Types of participants
Adults and children with severe malaria who are unable to take
medication by mouth.
Types of interventions
Intervention
• Intravenous, intramuscular or rectal artesunate.
Control
• Intravenous or intramuscular quinine.
Types of outcome measures
Primary outcomes
• Death.
Secondary outcomes
• Neurological sequelae.
• Coma recovery time.
• Time to hospital discharge.
• Fever clearance time.
• Parasite clearance time.
Adverse effects
• Serious adverse effects resulting in discontinuation of
treatment (eg biochemical abnormalities, cardiac effects).
• Hypoglycaemia (symptomatic or asymptomatic).
• Other adverse events, including tinnitus, hearing
impairment, nausea, and vomiting.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and on-
going).
Electronic searches
Databases
We searched the following databases using the search terms and
strategy described in Table 1: Cochrane Infectious Diseases Group
Specialized Register; Cochrane Central Register of Controlled Tri-
als (CENTRAL), published in The Cochrane Library; MEDLINE;
EMBASE; LILACS; and ISIWeb of Science.We also searched the
metaRegister of Controlled trials (mRCT) using artesunate and
quinine as search terms.
Searching other resources
Conference proceedings
We searched the following conference proceedings for relevant ab-
stracts: The 5th Multilateral Initiative on Malaria (MIM) Pan-
African Malaria Conference, 2 to 6 November 2009, Nairobi,
Kenya; the 4th MIM Pan-African Malaria Conference, 13 to
18 November 2005, Yaounde, Cameroon; the 4th European
Congress on Tropical Medicine, 11 to 15 September 2005, Mar-
seille, France; ACT NOW; the International Symposium on
Malaria, 29 to 30 April 2004, Colombia, New York, USA; the
2nd International Malaria Research Conference, John Hopkins
Malaria Research Institute, 25 to 26March 2004,Maryland,USA;
the 3rd MIM Pan-African Conference, 18 to 22 November 2002,
Arusha, Tanzania; and the 3rd European Congress on Tropical
Medicine and International Health, 8 to 12 September 2002, Lis-
bon, Portugal.
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Researchers, organizations, and pharmaceutical companies
We contacted individual researchers working in the field and the
World Health Organization (WHO) for details of unpublished
and ongoing trials.
Reference lists
We checked the reference lists of existing reviews and of all trials
identified by the above methods.
Data collection and analysis
Selection of studies
All trials identified by the search strategy were screened by two au-
thors working independently (Katharine Jones (KJ), Sarah Done-
gan (SD) or David Sinclair (DS)) and full reports of potentially
relevant trials were obtained. Two authors independently applied
the inclusion criteria to the full reports using an eligibility form
and scrutinized publications to ensure each trial was included in
the review only once. Trial authors were contacted for clarification
if necessary. Disagreement was resolved by discussion with David
Lalloo (DL).
Data extraction and management
Two authors independently extracted data using a data extrac-
tion form. For each outcome we aimed to extract the number of
participants randomised and the number analysed in each treat-
ment group. For dichotomous outcomes, we recorded the num-
ber of participants experiencing the event and the number as-
sessed in each treatment group. For continuous outcomes, we ex-
tracted arithmetic means and standard deviations for each treat-
ment group, together with the numbers assessed in each group.
Where medians were used we also extracted the range or intra-
quartile range.
Assessment of risk of bias in included studies
DS and SD independently assessed the risk of bias for each trial
using ’The Cochrane Collaboration’s tool for assessing the risk of
bias’ (Higgins 2008). We followed the guidance to assess whether
adequate steps had been taken to reduce the risk of bias across six
domains: sequence generation; allocation concealment; blinding
(of participants, personnel, and outcome assessors); incomplete
outcome data; selective outcome reporting; and other sources of
bias. We have categorized these judgments as ’yes’ (low risk of
bias), ’no’ (high risk of bias), or ’unclear’. Where our judgement is
unclear we attempted to contact the trial authors for clarification.
This information was used to guide the interpretation of the data
that are presented.
Measures of treatment effect
Results were calculated using risk ratio (RR) for dichotomous data,
and mean difference (MD) for continuous data. These effect esti-
mates are presented with 95% confidence intervals (CI).
Dealing with missing data
If there was discrepancy between the number randomized and the
number analysed, we calculated the percentage loss to follow up
for each treatment group and reported this information.
Originally, we aimed to analyse data according to the intention-to-
treat principle (all randomized participants should be analysed in
the groups to which they were originally assigned). However, since
for some trials it was unclear whether there was loss to follow up,
we entered the number analysed into ReviewManager 5 whenever
these figures were available. By attempting to carry out a complete-
case analysis in thisway,we have tried to avoidmaking assumptions
about the outcomes of participants that were lost to follow up.
Assessment of heterogeneity
We looked for statistical heterogeneity by inspecting the forest
plots for overlapping confidence intervals, applying the Chi2 test
(P value < 0.10 considered statistically significant), and the I2
statistic (I2 value of 50% used to denote moderate levels of het-
erogeneity).
Assessment of reporting biases
We planned to construct funnel plots to look for evidence of pub-
lication bias, provided there were sufficient included trials to make
this informative.
Data synthesis
We analysed the data using ReviewManager 5, and where possible
and appropriate we combined studies using a fixed-effect model.
If heterogeneity was detected but it was still considered clinically
meaningful to combine studies, a random-effects model was used.
Medians and ranges are only reported in tables.
If arithmetic means were reported, normality of the data was
checked by calculating the ratio of the mean over the standard de-
viation (Altman 1996). If this test suggested the data were skewed
(ie if the ratio was less than two), we commented on this in the
text but still combined the results in a meta-analysis.
Subgroup analysis and investigation of heterogeneity
We planned to investigate heterogeneity by conducting pre-spec-
ified sub-group analyses for the primary outcome. The potential
sources of heterogeneity were allocation concealment, blinding,
participant age (children versus adults), and drug regimen (loading
dose versus no loading dose of quinine and use of any additional
antimalarials).
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Sensitivity analysis
Post hoc, we conducted a sensitivity analysis to investigate the ro-
bustness of the results to differences in trial design, by subgroup-
ing the trials according to allocation concealment, participant age
(children versus adults), type of severe malaria (cerebral versus
non-cerebral malaria), geographical region, drug regimen (loading
dose versus no loading dose of quinine, and use of any additional
antimalarials), route of administration (intravenous versus intra-
muscular route), and time since admission to hospital.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The original search was conducted in November 2005 and iden-
tified 22 references of which four were duplicate trial reports. Six
unique trials fulfilled the eligibility criteria and were included in
the first version of this review.
An update search conducted in November 2010 identified a fur-
ther six trials of which two were eligible and these are now in-
cluded.
Included studies
The eight trials that met our inclusion criteria enrolled a total of
7429 participants (1664 adults and 5765 children).
Location
SIx trials were conducted in Asia; four took place in single cen-
tres in Vietnam (Anh 1989; Anh 1995; Cao 1997; Hien 1992),
Newton 2003 had two centres in Thailand; and Dondorp 2005
had 11 centres throughout Bangladesh, Myanmar, India, and In-
donesia. Of the two African studies; Eltahir 2010 was conducted
at a single study site in Sudan, and Dondorp 2010 had 11 cen-
tres in nine African countries (Mozambique, TheGambia, Ghana,
Kenya, Tanzania, Nigeria, Uganda, Rwanda, and the Democratic
Republic of the Congo).
Source of funding
Four trials were funded by a medical research charity (Cao 1997;
Dondorp 2005;Dondorp 2010;Newton 2003), one by theWHO
(Anh 1995), one by a private sugar company (Eltahir 2010), and
one received the study drugs fromapharmaceutical company (Anh
1989). Funding was not specified for Hien 1992.
Participants
Four trials enrolled only adults (Anh 1989; Anh 1995;Hien 1992;
Newton 2003), ofwhich three included only thosewith a diagnosis
of cerebral malaria (Anh 1989, Anh 1995, Hien 1992). Three
trials enrolled only children aged less than 15 years (Cao 1997;
Dondorp 2010; Eltahir 2010), and one enrolled both adults and
children (Dondorp 2005).
Dondorp 2005 and Dondorp 2010 used rapid diagnostic tests to
confirm P. falciparum parasitaemia, and all the other trials used
standard microscopy. Although standardized clinical definitions
for severemalaria exist, the entry criteria were not consistent across
trials.
Interventions
All trials compared artesunate with quinine, but the exact dosing
and route of administration varied between trials.
Three trials (Dondorp 2005; Dondorp 2010; Eltahir 2010) ad-
ministered both artesunate and quinine using the current recom-
mended dosing schedules (artesunate: 2·4 mg/kg (intravenous or
intramuscular) on admission, at 12 hours, at 24 hours, and then
once daily until starting oral therapy, quinine: 20 mg/kg intra-
venous or intramuscular loading dose, then 10 mg/kg every 8
hours until starting oral therapy).
Anh 1989, Anh 1995, and Hien 1992 gave 60 mg artesunate
intravenously at admission, 4 hours, 24 hours and 48 hours. Cao
1997 gave 3 mg/kg intramuscular on admission then 2 mg/kg
intramuscular at 12, 24, 48, and 72 hours, and Newton 2003 gave
2.4 mg/kg intravenously on admission, 1.2 mg/kg at 12 hours,
and then 1.2 mg/kg every 24 hours until able to swallow. Two
trials did not give the loading dose of quinine (Anh 1995; Hien
1992).
In addition six trials gave an additional oral antimalarial to at
least one of the treatment arms, which was unmatched between
the treatment arms (Anh 1989; Anh 1995; Cao 1997; Eltahir
2010; Hien 1992; Newton 2003). Two trials, Hien 1992 and Cao
1997, included an additional rectal artemisinin arm that was not
pertinent to this review.
Supportive care
All eight trials reported measuring blood glucose on admission,
but only five trials reported any subsequent active monitoring for
hypoglycaemia. Newton 2003 tested all participants several times
a day, Cao 1997 tested all participants with coma, prostration,
jaundice or more than one complication every four hours for the
first 24 hours and then every six hours, Anh 1989 tested all partic-
ipants on days 1, 3, 7, and 14, and Eltahir 2010 tested all partic-
ipants every six hours. Dondorp 2005 only measured blood glu-
cose in those participants with clinical signs of hypoglycaemia.
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Outcome measures (defined in Table 2)
All eight trials reported death as an outcome
Three trials reportedneurological sequelae at discharge (Cao 1997;
Dondorp 2005; Dondorp 2010). Six trials reported coma recovery
time (Anh 1989;Hien 1992; Anh 1995; Cao 1997; Newton 2003;
Eltahir 2010), and two trials reported time to eat, sit, and speak
(Dondorp 2005; Dondorp 2010).
Five trials reported fever clearance time (Hien 1992; Anh 1995;
Cao 1997; Newton 2003; Eltahir 2010). Reporting of parasite
clearance time varied between trials and includedparasite clearance
times of 50%, 90%, 95%, and 100%, of which parasite clearance
time of 50% was the most common (Anh 1989; Hien 1992; Anh
1995; Cao 1997; Newton 2003).
Four trials reported time to hospital discharge (Cao 1997; Newton
2003;Dondorp 2005;Dondorp 2010), and four trials reported ad-
verse effects including hypoglycaemia (Cao 1997; Newton 2003;
Dondorp 2005; Dondorp 2010).
Length of follow up
Cao 1997 specified that participants were asked to return for a
follow up visit three weeks after discharge from hospital, and
Dondorp 2010 followed those with neurological sequelae for 28
days. None of the other trials reported the length of follow-up.
Excluded studies
Sixteen trials detected by the search specifications were excluded
from the review (see ’Characteristics of excluded studies’).
Risk of bias in included studies
See Figure 1 for a summary of the risk of bias assessments. Further
details are presented in the ’Characteristics of included studies’
tables.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
The generation of the allocation sequence was adequate in all eight
trials and allocation concealment was adequate in six trials with
only Anh 1989 and Newton 2003 using open randomization.
Blinding
In all eight trials, investigators were aware of treatment allocation.
Participants were blind to the intervention in Hien 1992, and
microscopists and data analysts were blind to the intervention in
Dondorp 2005 and Dondorp 2010.
Incomplete outcome data
Newton 2003, Dondorp 2005 and Dondorp 2010 clearly state
that no participants were lost to follow-up. We were able to obtain
individual patient data for one trial in which primary outcomes
were available for all included participants (Cao 1997). For the
remaining trials the number of participants randomized was used
as the denominator in the analysis (Anh 1989; Hien 1992; Anh
1995; Eltahir 2010). As these were inpatient trials significant at-
trition is unlikely.
Selective reporting
No evidence of selective outcome reporting was detected.
Other potential sources of bias
No other sources of bias were identified.
Effects of interventions
See: Summary of findings for the main comparison; Summary
of findings 2
Death
Treatment with artesunate significantly reduced the risk of death
both in adults (RR 0.61, 95% CI 0.50 to 0.75; 1664 participants,
five trials, Analysis 1.1, Figure 2) and children (RR 0.76, 95% CI
0.65 to 0.90; 5765 participants, four trials, Analysis 1.1, Figure 2).
This reduction was consistent across all trials regardless of partici-
pant age or geographic region (I2 test for statistical heterogeneity
= 0%, Analysis 1.1).
Figure 2. Forest plot of comparison: 1 Artesunate vs quinine, outcome: 1.1 Death: participant age [Relative
effect].
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Mortality was lower in the trials recruiting children and conse-
quently the absolute reduction in mortality is lower than that seen
in adults (absolute risk reduction: adults: 94 fewer deaths per 1,000
patients, 95% CI 60 fewer to 120 fewer; children: 26 fewer deaths
per 1,000 patients, 95% CI 11 fewer to 38 fewer; see Summary
of findings 2 and Summary of findings for the main comparison).
This age effect is confounded by region, with the majority of the
data in children coming from Africa (where the trial mortality was
relatively low), and all the data in adults coming from Asia (where
the trial mortality was higher).
Three trials report a subgroup analyses of deaths occurring within
the first 48 hours following admission (Cao 1997; Dondorp 2005;
Newton 2003) and one trial reports the number of deaths occur-
ring within the first 24 hours (Dondorp 2010). Although the dif-
ference between groups did not reach statistical significance dur-
ing these early time periods there were consistently fewer deaths in
the groups treated with artesunate (6163 participants, four trials,
Analysis 1.2).
In view of the significant variation in trial design we conducted
sensitivity analyses excluding trials with inadequate allocation con-
cealment, trials only included patients with cerebral malaria, and
those with no loading dose of quinine, but these did not alter the
significance of the result.
The two large multicentre trials (Dondorp 2005; Dondorp 2010)
conducted multiple subgroup analyses according to the presence
or absence of coma, anaemia, shock, acidosis, respiratory distress,
or hyperparasitaemia at the time of admission. Mortality was con-
sistently lower with artesunate in all of these subgroups but some
were underpowered to show statistically significant differences.
Artesunate appears superior to quinine irrespective of intramus-
cular or intravenous administration (Analysis 1.3).
Neurological sequelae
At the time of hospital discharge, neurological sequelae were more
common in those treated with artesunate than with quinine (RR
1.41, 95%CI 1.05 to 1.88; 6422 participants, three trials, Analysis
1.4, Figure 3). Of these three trials, only Dondorp 2005 included
adults, and the incidence of neurological sequelae seems to be very
low in this group (Analysis 1.4, Figure 3).
Figure 3. Forest plot of comparison: 1 Artesunate vs quinine, outcome: 1.9 Neurological sequelae at
discharge.
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One trial in children (Dondorp 2010) followed participants up
until day 28 to see if these sequelae resolved. Of the 170 children
with sequelae at the time of discharge, 129 (75.9%) were avail-
able for assessment on day 28, and 68 of these (52.7%) had fully
recovered. At this time point the difference between groups was
not statistically significant (RR 1.23, 95% CI 0.74 to 2.03; 4857
participants, one trial, Analysis 1.5).
Coma recovery time
Six trials report a measure of coma recovery time (Anh 1989; Anh
1995; Cao 1997; Eltahir 2010; Hien 1992; Newton 2003). The
frequency of clinical monitoring to assess coma recovery varied
between these trials and is likely to have influenced the result (see
Table 2).
Three trials reported mean coma recovery time but the data from
Eltahir 2010 were incompletely reported. There is no evidence
of a difference between the groups, the data are skewed and the
results inconsistent (231 participants, two trials, Analysis 1.6).
Three trials reported median coma recovery time and again the
results were inconsistent and no conclusions can be made (see
Table 3).
In addition the two large multicentre trials (Dondorp 2005;
Dondorp 2010) report median time to speak, and Dondorp 2010
reports median time to localise pain (see Table 3). Dondorp 2010
found the time to speak and localise pain to be slightly prolonged
in those treated with artesunate but the clinical significance of this
is unclear (Table 3).
Time to hospital discharge
Three trials reported this outcome as a median (Cao 1997;
Dondorp 2005, Dondorp 2010). The results were consistent and
showed no evidence of a difference between the groups (see Table
3). One trial reported this outcome as a mean (Newton 2003)
with no evidence of a difference between the groups, but the data
appeared skewed (113 participants, one trial, Analysis 1.7).
Fever clearance time
Three trials reported this outcome as a mean (Hien 1992; Anh
1995; Eltahir 2010). There is no evidence of a difference between
the groups, although the data appeared to be skewed (317 partici-
pants, three trials, Analysis 1.8). Two trials reported this outcome
as a median (Cao 1997; Newton 2003), and found no statistically
significant difference between groups (see Table 3). The frequency
with which fever was monitored differed between the trials (Table
2).
Parasite clearance time (PCT)
Five trials report a measure of mean parasite clearance time.
Artesunate appears superior to quinine at reducing the mean 50%
PCT (MD -8.14 hrs, 95% CI -11.55 to -4.73; 292 participants,
three trials, Analysis 1.9), mean 90% PCT (MD -18.50 hrs, 95%
CI -24.13 to -12.87; 61 patients; one trial, Analysis 1.9), mean
95%PCT (MD -10.69 hrs, 95%CI -20.27 to -1.10, 231 patients;
two trials; Analysis 1.9), and mean 100% PCT (MD -9.77h 95%
CI -18.11 to -1.44, 419 patients; four trials; Analysis 1.9).
Two additional trials (Newton 2003; Cao 1997) reported median
50% and 90% PCT (see Table 3).
The frequency with which trials repeated malaria blood films dif-
fered between the trials (see Table 2).
Adverse effects
No trial reported discontinuation of medication. With the excep-
tion of hypoglycaemia and tinnitus, all adverse effects reported
could be attributable to malaria. Artesunate was associated with
a statistically significant reduction in episodes of hypoglycaemia
(RR 0.55, 95% 0.41 to 0.74; 7137 participants, 4 trials, Analysis
1.10, Figure 4).
13Artesunate versus quinine for treating severe malaria (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 4. Forest plot of comparison: 1 Artesunate vs quinine, outcome: 1.15 Hypoglycaemia episodes: by
age of participants.
Additional comments on adverse events taken from the original
trial reports are given in Table 4.
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D I S C U S S I O N
Summary of main results
Potential benefits of treating severe malaria with
artesunate instead of quinine
Treating severe malaria with artesunate instead of quinine reduces
the risk of death by 39% in adults (95% CI 25% to 50%), and
24% in children (95% CI 10% to 35%).
Artesunate also reduces episodes of hypoglycaemia during treat-
ment by 45% (95% CI 26% to 59%).
Potential harms of treating severe malaria with
artesunate instead of quinine
In adults neurological sequelae following treatment for severe
malaria appears to be very low (< 1 %) and no difference has been
shown between artesunate and quinine.
In children, treatment with artesunate appears to increase the in-
cidence of neurological sequelae at the time of hospital discharge
but the majority of these sequelae seem to resolve with time, and
there is no evidence of a difference between the two treatments 28
days later.
Overall completeness and applicability of
evidence
This review includes trials from multiple countries within Africa
and Asia where malaria is most prevalent. Although there are no
trials from South America it would be reasonable to generalise
these findings to all geographic regions.
There is now adequate evidence to be confident of the results in
both adults and children. However, it should be noted that these
trials did not include a significant number of pregnant women.
Based on this trial data the absolute benefit in children appears
lower than that seen in adults, primarily due to the lower mortal-
ity seen in children. This observation may be related to regional
differences rather than participant age as the majority of child data
is from Africa, and all the adult data is from Asia. Potential rea-
sons for the lower risk of mortality seen in children in Dondorp
2010 include: inclusion of ’less severe’ malaria, increased efficacy
of quinine in Africa or true differences in the risk of death related
to acquisition of partial immunity in Africa.
Quality of the evidence
Although several of the smaller trials suffer from methodological
problems such as open randomization, unmatched additional oral
antimalarials, or non-standard dosing, these do not affect the over-
all quality of the evidence as the majority of the data is from large
multicentre trials which do not suffer the same problems.
We consider the evidence for a reduction in mortality with arte-
sunate to be high quality, and further research to establish this is
unnecessary (see Summary of findings for the main comparison
and Summary of findings 2).
The increase in neurological sequelae is of a smaller magnitude
than the reduction in deaths and seems to be temporary. The bal-
ance of benefits and harms is in favour of benefit with artesunate.
Economic commentary
To supplement the main systematic review of the effects on arte-
sunate in the management of severe malaria, we sought to iden-
tify economic evaluations which compared the use of artesunate
with the use of quinine. Systematic supplementary searches of the
NHS Economic EvaluationDatabase (NHS EED) and theHealth
Economic Evaluations Database (HEED) identified four articles
using the search terms outlined in Table 1. The articles were then
screened for inclusion and two were discarded as they evaluated
the use of rectal artesunate.
Lubell 2009 is a cost-effectiveness analysis based on the large mul-
ticentre trial of artesunate in Asia (Dondorp 2005), and Lubell
2011 is based on the large multicentre trial from sub-Saharan
Africa (Dondorp 2010). Both studies take the service-provider’s
perspective, calculating the total costs to the health service, and
no estimate was made of the economical benefit to the individual
or society.
In both studies, the total cost of care using artesunate was
marginally higher per patient thanusing quinine (inAsia:US$43.0
vs. US$32.4; in Africa: US$66.5 vs. US$63.5). However, given
the large treatment effect of artesunate, the incremental cost per
additional death averted was less than US$140 in both studies.
For a brief summary of these two studies see Table 5.
It is important to highlight that neither of the identified economic
evaluations were subjected to any formal critical appraisal and we
do not attempt to draw any firm or general conclusions regarding
the relative costs or efficiency of artesunate compared with quinine
for the treatment of severemalaria.However, the available evidence
indicates that, from an economic perspective, the use of artesunate
for the treatment of severe malaria is a promising strategy when
compared with quinine. Combined with the clinical data and the
WHO treatment guidelines, this information may prove useful to
those with responsibility for making local, regional, or national
decisions regarding the management of individuals with severe
malaria. However, end users of this review will need to assess the
extent to which the economic evidence presented here may be
applicable to their own setting.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Intravenous artesunate should be the treatment of choice for adults
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and children presenting with severe malaria in any geographical
region.
Implications for research
Further research to examine the efficacy of artesunate versus qui-
nine in children and adults is unnecessary. The safety of artesunate
in pregnancy still needs to be determined, and trials are underway
to examine the effects of artesunate when given repeatedly formul-
tiple episodes of malaria. Toxicity from repeated dosing can not
be ruled out on the basis of the evidence included in this review.
Particular attention should be paid to the incidence of neurologi-
cal sequelae.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Anh 1989
Methods Study design: An open label randomized controlled trial
Study dates: Feb to Dec 1989
Participants Number: 41 enrolled
Inclusion criteria: adults > 16 yr old with cerebral malaria (P. falciparum parasitaemia >
1000/mm3 and Glasgow Coma Scale of 14 or less not attributable to any cause other
than malaria)
Exclusions: not specified
Interventions 1. Artesunate: 60 mg intravenous (IV) at 0, 4, 24, and 48 h
2. Quinine: 20 mg/kg IV loading dose over 4 h at 0 h then 10 mg/kg IV every 8 h until
able to swallow then 10 mg/kg by mouth every 8 h until day 7
Additional antimalarials: none reported
Outcomes 1. Death
2. Coma recovery time
3. Parasite clearance time of 50%
4. Parasite clearance time of 95%
Notes Location: Vietnamese hospital
Transmission: not specified
Funding: Roche Asian Research Foundation supplied artesunate (personal communica-
tion from author)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Personal communication with author:
Random numbers table
Allocation concealment (selection bias) High risk Comment: Not done
Blinding (performance bias and detection
bias)
Objective outcomes: Death
Low risk Comment: An open-label trial is unlikely
to bias an objective outcome like death
Blinding (performance bias and detection
bias)
Subjective outcomes: Others
High risk Comment: An open label trial. No attempt
was made to blind participants, providers
or outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up occurred
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Anh 1989 (Continued)
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Anh 1995
Methods Study design: An open label randomized controlled trial
Study dates: Jul 1992 to May 1995
Participants Number: 190 enrolled
Inclusion criteria: adults 15 to 65 yr with cerebral malaria (asexual P. falciparum par-
asitaemia and clinical signs of cerebral malaria alone or associated with other visceral
complications)
Exclusion criteria: associated P. vivax parasitaemia, pregnancy, and concomitant diseases
such as diabetes mellitus, stroke, meningitis, head trauma, pulmonary tuberculosis, or
AIDS
Interventions 1. Artesunate: 60 mg intravenous (IV) at 0, 4, 24, and 48 h
2. Quinine: 10 mg/kg IV over 4 h at 0 h then 10 mg/kg IV every 8 h until able to
swallow then quinine by mouth at similar doses every 8 h until day 7
Additional antimalarials: artesunate treatment arm given one dose of mefloquine by
mouth 15 mg/kg at day 7; quinine none
Outcomes 1. Death within 24 h
2. Death after 24 h
3. Coma recovery time
4. Fever clearance time
5. Parasite clearance time of 50%
6. Parasite clearance time of 95%
7. Parasite clearance time of 100%
Not included in the review:
8. Time to sit
9. Time to take oral by self medication
Notes Location: Vietnamese clinical research centre
Transmission: not specified
Funding: World Health Organization
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Personal communication with author:
Central randomization
Allocation concealment (selection bias) Low risk Personal communication with author:
Central randomization
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Anh 1995 (Continued)
Blinding (performance bias and detection
bias)
Objective outcomes: Death
Low risk Comment: An open-label trial is unlikely
to bias an objective outcome like death
Blinding (performance bias and detection
bias)
Subjective outcomes: Others
High risk Comment: An open label trial. No attempt
was made to blind participants, providers
or outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up are recorded
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Cao 1997
Methods Study design: A 3-arm open label randomized controlled trial
Study dates: Aug 1992 to Mar 1995
Participants Number: 72 enrolled
Inclusion criteria: children < 15 yr with severe malaria (asexual P. falciparum parasitaemia
plus at least 1 of the following: coma (Blantyre Coma Scale less than or equal to 3),
severe anaemia (capillary haematocrit < 15%) with parasitaemia (> 10,000/µL); hyper-
parasitaemia (> 10% parasitized red blood cells or parasitaemia > 500,000/µL); jaundice
(obvious clinically or serum bilirubin > 48 µmol/L); hypoglycaemia (blood glucose <
2.2 mmol/L); spontaneous bleeding (eg gastrointestinal haemorrhage); shock (systolic
blood pressure < 50 mmHg if aged < 6 yr, or < 70 mmHg if aged 6 to 14 yr); repeated
generalized convulsions (3 or more in 24 h despite cooling); renal impairment (serum
creatinine > 177 µmol/L, or urine output < 12 mL/kg/24 h that fails to improve despite
rehydration)
Exclusion criteria: severe diarrhoea, mixed infection with P. vivax, prior treatment with
quinine > 60 mg/kg, artemisinin > 20 mg/kg, or artesunate > 2 mg/kg during the illness
episode, or any antimalarial treatment continuing for > 48 h
Interventions 1. Artesunate: 3 mg/kg intramuscular (IM) at 0 h then 2 mg/kg IM at 12, 24, 48, and
72 h
2. Quinine: 20 mg/kg intravenous (IV) loading dose over 4 h (omitted if pretreatment
with quinine) then 10 mg/kg IV every 8 h up to day 7
3. [Not relevant to review: rectal artemisinin]
Additional antimalarials given: artesunate treatment arm received one dose ofmefloquine
by mouth 15 mg/kg at 96 h; quinine treatment arm given one dose of sulfadoxine-
pyrimethamine 500 mg/25 mg on day 7
Outcomes 1. Death
2. Number survived with neurological sequelae
3. Fever clearance time (all patients, excluding superinfections)
4. Coma resolution
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Cao 1997 (Continued)
5. Parasite clearance time of 50%
6. Parasite clearance time of 90%
7. Parasite clearance time of 100%
8. Period in hospital
9. Hypoglycaemia
10. Adverse effects
Not included in this review:
11. Number survived well
12. Time to death from admission
13. Number with acute renal failure
14. Shock
15. Convulsions
16. Deterioration of coma score
17. Gastrointestinal bleeding
18. Anaemia
19. Chest infection
20. Urinary tract infection
21. Other infection
22. Reticulocyte count at admission, on day 5, at discharge
23. Haematocrit at admission, on day 5, at discharge
Notes Location: Vietnamese hospital
Transmission: not specified
Funding: Wellcome Trust of Great Britain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Personal communication with author:
Computer generated
Allocation concealment (selection bias) Low risk Quote: ’Randomization slips were kept in
sealed, consecutively numbered envelopes
and opened only after a decision to include
the patient in the study had been made’
Blinding (performance bias and detection
bias)
Objective outcomes: Death
Low risk Comment: An open-label trial is unlikely
to bias an objective outcome like death
Blinding (performance bias and detection
bias)
Subjective outcomes: Others
High risk Comment: An open label trial. No attempt
was made to blind participants, providers
or outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Personal communication from author:
100% analysed, no losses to follow-up
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Cao 1997 (Continued)
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Dondorp 2005
Methods Study design: An open label multi-centre randomized controlled trial
Study dates: Jun 2003 to May 2005
Participants Number: 1461 enrolled
Inclusion criteria: adults and children > 2 yr with severe malaria (positive blood antigen
stick test for P. falciparum and a diagnosis of severe malaria, according to the admitting
physician)
Exclusion criteria: convincing history of full treatment with quinine (40 mg/kg on the
first day and 30 mg/kg on any subsequent day) or an artemisinin derivative for more
than 24 h before admission, known allergy to 1 of the artemisinin derivatives or quinine
Interventions 1. Artesunate: 2.4 mg/kg intravenous (IV) at 0, 12, and 24 h then 2.4 mg/kg IV every
24 h until able to swallow then 2 mg/kg by mouth until day 7
2. Quinine: 20 mg/kg IV loading dose then 10 mg/kg every 8 h until able to swallow
then 10 mg/kg by mouth every 8 h until day 7
Additional antimalarials: both arms except in India and Bangladesh were given doxycy-
cline (100 mg every 12 h for 7 d) once able to swallow
Outcomes 1. In-hospital death
2. Death within 48 h of entry
3. Death after 48 h of entry
4. In-hospital death (blood-smear positive)
5. Neurological sequelae
6. Time to discharge (median, intra quartile range, and range)
7. Hypoglycaemia after entry
Not included in the review:
8. Combined outcome: in hospital death or neurological sequelae
9. Fetal death
10. Time to speak (median, intra quartile range, and range)
11. Time to eat (median, intra quartile range, and range)
12. Time to sit (median, intra quartile range, and range)
13. Convulsions after entry
14. Shock developing after entry
15. Blackwater fever developing after entry
16. Dialysis after entry
17. Vasopressor treatment after entry
18. Mechanical ventilation after entry
Notes Location: hospitals in Bangladesh, Myanmar, India, and Indonesia
Transmission: not specified
Funding: Wellcome Trust grant
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Dondorp 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’The two-step randomisation was
produced with a computer generated ran-
domisation list’
Allocation concealment (selection bias) Low risk Quote: ’After informed consent was ob-
tained, we signed and dated a numbered
sealed envelope across the seal, then opened
it to reveal a unique study number. This
number did not indicate the treatment al-
location, but referred to a separate sealed
hardcover box, containing the study drug,
case record form, and all disposables needed
for drug administration and blood sam-
pling’
Blinding (performance bias and detection
bias)
Objective outcomes: Death
Low risk Comment: An open-label trial is unlikely
to bias an objective outcome like death
Blinding (performance bias and detection
bias)
Subjective outcomes: Others
High risk Comment: An open label trial.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up are recorded.
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Dondorp 2010
Methods Study design: An open label, multi-centre randomized controlled trial
Study dates: Oct 2005 to July 2010
Participants Number: enrolled
Inclusion criteria: Age < 15 years (age criteria varied slightly between sites at the request
of the respective ethics review boards), a positive rapid diagnostic test for P. falciparum,
severe malaria (physicians opinion), written consent
Exclusions: Prior full treatment with parenteral quinine, or an artemisinin derivative for
more than 24 h
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Dondorp 2010 (Continued)
Interventions Each study site used either the intravenous or intramuscular route for both treatment
arms
1. Artesunate (Guilin, China): 2·4 mg/kg on admission, at 12 h, at 24 h, and then once
daily until starting oral therapy.
2. Quinine dihydrochloride (Indus Pharma, Pakistan): 20 mg salt per kg loading dose
infused over 4 h (in 5-10 mL/kg of 5% dextrose), followed by a 10mg salt per kg infusion
over 2-8 h three times daily until starting oral therapy
(For intramuscular treatment the doses were the same as for intravenous treatment;
quinine was diluted in normal saline to a concentration of 60 mg/mL, and injected into
the anterior thigh. The loading dose was given as a split dose into each thigh)
Once able to tolerate oral medication (but after a minimum of 24 h of parenteral treat-
ment), all participants received oral artemether-lumefantrine (Novartis, Switzerland) for
3 days with milk or fat)
Outcomes 1. Death
2. Death or sequelae at 28 days
3. Malaria attributable mortality
4. Case fatality in HIV +ve children
5. Time to discharge
3. Neurological sequelae
4. Adverse events
Not included in the review:
1. Development of coma
2. Convulsions developing after 6 hours
3. Severe anaemia after admission
4. Blackwater fever
5. Time to speak (median, intra quartile range)
6. Time to eat (median, intra quartile range)
7. Time to sit unsupported (median, intra quartile range)
8. Time to localise pain (median, intra quartile range)
Notes Location: 11 centres in nine African countries (Mozambique, The Gambia, Ghana,
Kenya,
Tanzania, Nigeria, Uganda, Rwanda, and Democratic Republic of the Congo)
Transmission: variable
Funding: The Wellcome Trust
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’Randomisation was done by peo-
ple unrelated to the study and provided to
the study sites in blocks of 20’
Allocation concealment (selection bias) Low risk Quote: ’Study numbers were kept inside
opaque sealed paper envelopes. After full
informedwritten consentwas obtained, the
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Dondorp 2010 (Continued)
next envelope, which contained a unique
study box number, was opened by the study
physician or nurse. Then the correspond-
ing numbered sealed box was opened. This
box contained the study drug, case record
form (labelled with the unique study num-
ber), and all disposables needed for drug
administration and blood
sampling’.
Blinding (performance bias and detection
bias)
Objective outcomes: Death
Low risk Comment: An open-label trial is unlikely
to bias an objective outcome like death
Blinding (performance bias and detection
bias)
Subjective outcomes: Others
High risk Quote: ’Although the trial was open label
at each site, none of the investigators or
triallists, apart from for the trial statisti-
cian (TEP), had access to the summaries of
treatment allocations. When notes or case
record forms were reviewed, all study drug
details were removed to preserve masking’
Incomplete outcome data (attrition bias)
All outcomes
Low risk All randomised participants are included
in the primary analysis. A secondary per-
protocol analysis including only those with
provenmalaria who received the full course
of treatment excluded 149 (5.5%) from the
artesunate arm and 161 (5.9%) from the
quinine arm
Selective reporting (reporting bias) Low risk No evidence of selective reporting.
Other bias Low risk One study site did study adults as well as
children but these participants are not re-
ported in the paper, or analysis
Eltahir 2010
Methods Study design: An open label randomized controlled trial
Study dates: Aug to Sep 2009
Participants Number: 66 enrolled
Inclusion criteria: Children with slide-confirmed, severe P. falciparum malaria, written
informed consent
Exclusions: None stated
Interventions 1. Intravenous artesunate (Guilin; China): 2.4 mg/kg body weight given at 0, 12, and
24 h, and then daily.
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Eltahir 2010 (Continued)
2. Intravenous quinine (Shanghai; China): 20 mg/kg loading dose infused over 4 h then
10 mg/kg infused over 2-4 h three times a day
Once oral therapy was tolerated participants received artesunate+ sulfadoxine-
pyrimethamine or quinine tablets to complete treatment
Outcomes 1. Death
2. Coma recovery time
3. Parasite clearance time
4. Fever clearance time
5. Adverse events
Not included in the review:
Notes Location: Sudan
Transmission: unstable
Funding: Sudanese Sugar Company and Assalaya Sugar Factory, Sudan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: ’Individuals were randomised (by
computer-generated numbers)’
Allocation concealment (selection bias) Low risk Quote: ’computer generated numbers were
sealed in individual envelopes and securely
stored’
Blinding (performance bias and detection
bias)
Objective outcomes: Death
Low risk Comment: An open-label trial is unlikely
to bias an objective outcome like death
Blinding (performance bias and detection
bias)
Subjective outcomes: Others
High risk Comment: An open label trial. No attempt
was made to blind participants, providers
or outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
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Hien 1992
Methods Study design: A 3-arm open label randomized controlled trial
Study dates: 1989 to 1990
Participants Number: 61 enrolled
Inclusion criteria: cerebral malaria (P. falciparum parasitaemia with clinical signs of
malaria and a Glasgow Coma Scale < 10)
Exclusion criteria: not specified
Interventions 1. Artesunate: 60 mg intravenous (IV) at 0, 4, 24, and 48 h
2. Quinine: 500 mg IV over 4 h then 500 mg IV every 8 h until able to swallow then
500 mg by mouth every 8 h until day 14
3. [Not relevant to review: rectal artemisinin]
Additional antimalarials: artesunate treatment arm given one dose of mefloquine (by
mouth 500 mg) once able to swallow
Outcomes 1. Fever clearance time
2. Parasite clearance time of 50%
3. Parasite clearance time of 90%
4. Parasite clearance time of 100%
5. Time to regain full consciousness
6. Death
Not included in the review:
Notes Location: intensive care unit in Vietnam
Transmission: not specified
Funding: artesunate was provided by Professor Li Guo Qiao
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Personal communication from author: We
did randomization by hand using tables of
randomization from a statistic book
Allocation concealment (selection bias) Low risk Personal communication from author: All
treatment codes were sealed in opaque en-
velopes which were only opened when pa-
tients had been recruited into trial based on
inclusion criteria
Blinding (performance bias and detection
bias)
Objective outcomes: Death
Low risk Comment: An open-label trial is unlikely
to bias an objective outcome like death
Blinding (performance bias and detection
bias)
Subjective outcomes: Others
High risk Comment: An open label trial. No attempt
was made to blind participants, providers
or outcome assessors
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Hien 1992 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk No losses to follow-up are recorded
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
Newton 2003
Methods Study design: An open label randomized controlled trial
Study dates: May to July 1994 and 1995 to 2001
Participants Number: 113 enrolled, 100 analysed
Inclusion criteria: adults aged 15 yr or above with severe malaria (single-species P. fal-
ciparum parasitaemia > 0.1% plus at least 1 of following: Glasgow Coma Scale < 11;
haematocrit < 20% with asexual parasitaemia > 100,000/µL; total serum bilirubin > 50
µmol/L with asexual parasitaemia > 100,000/µL; serum creatinine > 264 mol/µL with
urine output < 400 mL/24 h; systolic blood pressure < 80 mmHg with cool extremities;
asexual parasitaemia > 10%; plasma lactate level > 4 mmol/L; plasma glucose level < 2.
2 mmol/L; plasma venous bicarbonate level < 15 mmol/L
Exclusion criteria: pregnancy, contraindications to study drugs, artesunate, mefloquine,
or significant quinine (> 2 g) intake in the previous 24 h
Interventions 1. Artesunate: 2.4 mg/kg intravenous (IV) at 0 h then 1.2 mg/kg at 12 h then 1.2 mg/
kg every 24 h until able to swallow then 12 mg/kg by mouth every 24 h over 7 days
2. Quinine: 20 mg/kg IV over 4 h loading dose then 10 mg/kg IV every 8 until able to
swallow then 10 mg/kg by mouth until day 7
Additional antimalarials: once able to swallow some participants in both arms were given
additional antimalarials, but the drug given varied during the trial; AS: no additional
antimalarial (n = 22), mefloquine 15 mg/kg (n = 1), mefloquine 25 mg/kg in 2 doses (n =
22), doxycycline 100 mg every 12 h for 7 d (n = 14); quinine: no additional antimalarial
(n = 20), tetracycline 250 mg every 12 h for 7 d (n = 19), doxycycline 100 mg every 12
h for 7 days (n = 15)
Outcomes 1. Fever clearance time
2. Parasite clearance time of 50%
3. Parasite clearance time of 90%
4. Parasite clearance time of 100%
5. Time to regain full consciousness
6. Death
6. Hypoglycaemia
7. Adverse effects
Not included in the review:
Notes Location: 2 hospitals in Thailand
Transmission: seasonal low intensity
Funding: Wellcome Trust of Great Britain
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Newton 2003 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Personal communication with author:
Random codes were created in Excel using
the ’Randbetween’ command
Allocation concealment (selection bias) High risk Quote: ’The randomization was open’
Blinding (performance bias and detection
bias)
Objective outcomes: Death
Low risk Comment: An open-label trial is unlikely
to bias an objective outcome like death
Blinding (performance bias and detection
bias)
Subjective outcomes: Others
High risk Comment: An open label trial. No attempt
was made to blind participants, providers
or outcome assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk 13 patients were excluded after randomiza-
tion for not meeting the criteria for severe
malaria 5 (%) in the artesunate arm and 8
(%) in the quinine arm
Selective reporting (reporting bias) Low risk No evidence of selective reporting
Other bias Low risk No other bias identified
n: number of participants.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Aguwa 2010 Artemether versus quinine
Awad 2003 Not a randomized controlled trial
Barnes 2004 Not severe malaria
Bounyasong 2001 Not severe malaria
Haroon 2005 A quasi-randomized controlled trial in which the first patient was allocated a treatment at random and then
future patients were allocated their treatment using an alternating pattern
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(Continued)
Krudsood 2003 Not a randomized controlled trial
Li 1990 Not severe malaria
McGready 2001a Not severe malaria
McGready 2001b Not a randomized controlled trial
Mohanty 2004 Not a randomized controlled trial (quasi-randomized)
Newton 2001 Treatment comparison is artesunate versus artesunate and quinine
Osanuga 2009 Artemether versus quinine
Phu 2010 Artesunate versus artemether
Pukrittayakamee 2004 Not severe malaria
Win 1992 Not a randomized controlled trial
Zhao 2001 Not severe malaria
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D A T A A N D A N A L Y S E S
Comparison 1. Artesunate vs quinine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Death: participant age 8 7429 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.62, 0.80]
1.1 Adults (Age > 15/16 years) 5 1664 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.50, 0.75]
1.2 Children (Age < 15 years) 4 5765 Risk Ratio (M-H, Fixed, 95% CI) 0.76 [0.65, 0.90]
2 Death: time since admission to
hospital [sensitivity analysis]
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Death within 24 hours 1 5417 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.69, 1.04]
2.2 Death after 24 hours 1 5072 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.48, 0.88]
2.3 Death within 48 hours 3 1646 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.57, 1.05]
2.4 Death after 48 hours 3 1646 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.38, 0.74]
3 Death: intravenous vs
intramuscular artesunate
[sensitivity analysis]
8 7429 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.63, 0.80]
3.1 Intravenous artesunate 7 5435 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.60, 0.80]
3.2 Intramuscular artesunate 2 1994 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.60, 0.98]
4 Neurological sequelae at
discharge
3 6422 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [1.05, 1.88]
4.1 Adults (age > 15/16 years) 1 1259 Risk Ratio (M-H, Fixed, 95% CI) 2.97 [0.60, 14.64]
4.2 Children (Age < 15 years) 3 5163 Risk Ratio (M-H, Fixed, 95% CI) 1.36 [1.01, 1.83]
5 Neurological sequelae at day 28 1 4857 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.74, 2.03]
5.1 Adults (Age > 15/16 years) 0 0 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5.2 Children (Age < 15 years) 1 4857 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.74, 2.03]
6 Coma recovery time (hours) 2 231 Mean Difference (IV, Random, 95% CI) 2.11 [-19.17, 23.40]
7 Time to hospital discharge (days) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Fever clearance time (hours) 3 317 Mean Difference (IV, Random, 95% CI) -2.74 [-14.07, 8.60]
9 Parasite clearance time (hours) 5 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Time to clear 50% of
parasites
3 292 Mean Difference (IV, Random, 95% CI) -8.14 [-11.55, -4.73]
9.2 Time to clear 90% of
parasites
1 61 Mean Difference (IV, Random, 95% CI) -18.5 [-24.13, -12.
87]
9.3 Time to clear 95% of
parasites
2 231 Mean Difference (IV, Random, 95% CI) -10.69 [-20.27, -1.
10]
9.4 Time to clear all parasites 4 419 Mean Difference (IV, Random, 95% CI) -9.77 [-18.11, -1.44]
10 Hypoglycaemia episodes: by
age of participants
5 7137 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.41, 0.74]
10.1 Adults (> 15/16 years) 2 1372 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.19, 0.68]
10.2 Children (Age < 15
years)
4 5765 Risk Ratio (M-H, Fixed, 95% CI) 0.62 [0.45, 0.87]
11 Hypoglycaemia episodes: by
method of monitoring
5 7137 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.41, 0.74]
11.1 Routine monitoring 3 251 Risk Ratio (M-H, Fixed, 95% CI) 0.46 [0.25, 0.85]
11.2 Clinical monitoring 1 1461 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.13, 0.79]
11.3 Unclear 1 5425 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.45, 0.92]
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Analysis 1.1. Comparison 1 Artesunate vs quinine, Outcome 1 Death: participant age.
Review: Artesunate versus quinine for treating severe malaria
Comparison: 1 Artesunate vs quinine
Outcome: 1 Death: participant age
Study or subgroup Artesunate Quinine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults (Age > 15/16 years)
Anh 1989 2/19 7/22 1.3 % 0.33 [ 0.08, 1.41 ]
Anh 1995 8/99 18/91 3.6 % 0.41 [ 0.19, 0.89 ]
Dondorp 2005 102/633 153/626 29.9 % 0.66 [ 0.53, 0.83 ]
Hien 1992 5/31 8/30 1.6 % 0.60 [ 0.22, 1.64 ]
Newton 2003 7/59 12/54 2.4 % 0.53 [ 0.23, 1.26 ]
Subtotal (95% CI) 841 823 38.8 % 0.61 [ 0.50, 0.75 ]
Total events: 124 (Artesunate), 198 (Quinine)
Heterogeneity: Chi?? = 2.23, df = 4 (P = 0.69); I?? =0.0%
Test for overall effect: Z = 4.70 (P < 0.00001)
2 Children (Age < 15 years)
Cao 1997 4/37 5/35 1.0 % 0.76 [ 0.22, 2.59 ]
Dondorp 2005 5/97 11/105 2.1 % 0.49 [ 0.18, 1.37 ]
Dondorp 2010 230/2712 297/2713 57.7 % 0.77 [ 0.66, 0.91 ]
Eltahir 2010 1/33 2/33 0.4 % 0.50 [ 0.05, 5.25 ]
Subtotal (95% CI) 2879 2886 61.2 % 0.76 [ 0.65, 0.90 ]
Total events: 240 (Artesunate), 315 (Quinine)
Heterogeneity: Chi?? = 0.87, df = 3 (P = 0.83); I?? =0.0%
Test for overall effect: Z = 3.31 (P = 0.00092)
Total (95% CI) 3720 3709 100.0 % 0.71 [ 0.62, 0.80 ]
Total events: 364 (Artesunate), 513 (Quinine)
Heterogeneity: Chi?? = 5.60, df = 8 (P = 0.69); I?? =0.0%
Test for overall effect: Z = 5.45 (P < 0.00001)
Test for subgroup differences: Chi?? = 2.69, df = 1 (P = 0.10), I?? =63%
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Analysis 1.2. Comparison 1 Artesunate vs quinine, Outcome 2 Death: time since admission to hospital
[sensitivity analysis].
Review: Artesunate versus quinine for treating severe malaria
Comparison: 1 Artesunate vs quinine
Outcome: 2 Death: time since admission to hospital [sensitivity analysis]
Study or subgroup Artesunate Quinine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Death within 24 hours
Dondorp 2010 158/2709 187/2708 100.0 % 0.84 [ 0.69, 1.04 ]
Subtotal (95% CI) 2709 2708 100.0 % 0.84 [ 0.69, 1.04 ]
Total events: 158 (Artesunate), 187 (Quinine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
2 Death after 24 hours
Dondorp 2010 69/2551 105/2521 100.0 % 0.65 [ 0.48, 0.88 ]
Subtotal (95% CI) 2551 2521 100.0 % 0.65 [ 0.48, 0.88 ]
Total events: 69 (Artesunate), 105 (Quinine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.83 (P = 0.0046)
3 Death within 48 hours
Cao 1997 3/37 3/35 3.5 % 0.95 [ 0.20, 4.38 ]
Dondorp 2005 61/730 75/731 85.7 % 0.81 [ 0.59, 1.12 ]
Newton 2003 4/59 9/54 10.7 % 0.41 [ 0.13, 1.24 ]
Subtotal (95% CI) 826 820 100.0 % 0.78 [ 0.57, 1.05 ]
Total events: 68 (Artesunate), 87 (Quinine)
Heterogeneity: Chi?? = 1.43, df = 2 (P = 0.49); I?? =0.0%
Test for overall effect: Z = 1.65 (P = 0.098)
4 Death after 48 hours
Cao 1997 1/37 2/35 2.2 % 0.47 [ 0.04, 4.99 ]
Dondorp 2005 46/730 89/731 94.5 % 0.52 [ 0.37, 0.73 ]
Newton 2003 3/59 3/54 3.3 % 0.92 [ 0.19, 4.34 ]
Subtotal (95% CI) 826 820 100.0 % 0.53 [ 0.38, 0.74 ]
Total events: 50 (Artesunate), 94 (Quinine)
Heterogeneity: Chi?? = 0.50, df = 2 (P = 0.78); I?? =0.0%
Test for overall effect: Z = 3.78 (P = 0.00015)
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Analysis 1.3. Comparison 1 Artesunate vs quinine, Outcome 3 Death: intravenous vs intramuscular
artesunate [sensitivity analysis].
Review: Artesunate versus quinine for treating severe malaria
Comparison: 1 Artesunate vs quinine
Outcome: 3 Death: intravenous vs intramuscular artesunate [sensitivity analysis]
Study or subgroup Artesunate Quinine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Intravenous artesunate
Anh 1989 2/19 7/22 1.3 % 0.33 [ 0.08, 1.41 ]
Anh 1995 8/99 18/91 3.7 % 0.41 [ 0.19, 0.89 ]
Dondorp 2005 107/730 164/731 32.0 % 0.65 [ 0.52, 0.81 ]
Dondorp 2010 139/1779 171/1724 33.9 % 0.79 [ 0.64, 0.98 ]
Eltahir 2010 1/33 2/33 0.4 % 0.50 [ 0.05, 5.25 ]
Hien 1992 5/31 8/30 1.6 % 0.60 [ 0.22, 1.64 ]
Newton 2003 7/59 12/54 2.4 % 0.53 [ 0.23, 1.26 ]
Subtotal (95% CI) 2750 2685 75.1 % 0.69 [ 0.60, 0.80 ]
Total events: 269 (Artesunate), 382 (Quinine)
Heterogeneity: Chi?? = 4.91, df = 6 (P = 0.56); I?? =0.0%
Test for overall effect: Z = 4.98 (P < 0.00001)
2 Intramuscular artesunate
Cao 1997 4/37 5/35 1.0 % 0.76 [ 0.22, 2.59 ]
Dondorp 2010 91/933 126/989 23.8 % 0.77 [ 0.59, 0.99 ]
Subtotal (95% CI) 970 1024 24.9 % 0.77 [ 0.60, 0.98 ]
Total events: 95 (Artesunate), 131 (Quinine)
Heterogeneity: Chi?? = 0.00, df = 1 (P = 0.99); I?? =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
Total (95% CI) 3720 3709 100.0 % 0.71 [ 0.63, 0.80 ]
Total events: 364 (Artesunate), 513 (Quinine)
Heterogeneity: Chi?? = 5.40, df = 8 (P = 0.71); I?? =0.0%
Test for overall effect: Z = 5.36 (P < 0.00001)
Test for subgroup differences: Chi?? = 0.48, df = 1 (P = 0.49), I?? =0.0%
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Analysis 1.4. Comparison 1 Artesunate vs quinine, Outcome 4 Neurological sequelae at discharge.
Review: Artesunate versus quinine for treating severe malaria
Comparison: 1 Artesunate vs quinine
Outcome: 4 Neurological sequelae at discharge
Study or subgroup Artesunate Quinine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults (age > 15/16 years)
Dondorp 2005 6/633 2/626 2.7 % 2.97 [ 0.60, 14.64 ]
Subtotal (95% CI) 633 626 2.7 % 2.97 [ 0.60, 14.64 ]
Total events: 6 (Artesunate), 2 (Quinine)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
2 Children (Age < 15 years)
Cao 1997 1/33 0/30 0.7 % 2.74 [ 0.12, 64.69 ]
Dondorp 2005 1/97 1/105 1.3 % 1.08 [ 0.07, 17.07 ]
Dondorp 2010 99/2482 71/2416 95.4 % 1.36 [ 1.01, 1.83 ]
Subtotal (95% CI) 2612 2551 97.3 % 1.36 [ 1.01, 1.83 ]
Total events: 101 (Artesunate), 72 (Quinine)
Heterogeneity: Chi?? = 0.21, df = 2 (P = 0.90); I?? =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
Total (95% CI) 3245 3177 100.0 % 1.41 [ 1.05, 1.88 ]
Total events: 107 (Artesunate), 74 (Quinine)
Heterogeneity: Chi?? = 1.10, df = 3 (P = 0.78); I?? =0.0%
Test for overall effect: Z = 2.30 (P = 0.022)
Test for subgroup differences: Chi?? = 0.88, df = 1 (P = 0.35), I?? =0.0%
0.01 0.1 1 10 100
Favours artesunate Favours quinine
39Artesunate versus quinine for treating severe malaria (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Artesunate vs quinine, Outcome 5 Neurological sequelae at day 28.
Review: Artesunate versus quinine for treating severe malaria
Comparison: 1 Artesunate vs quinine
Outcome: 5 Neurological sequelae at day 28
Study or subgroup Artesunate Quinine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults (Age > 15/16 years)
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (Artesunate), 0 (Quinine)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Children (Age < 15 years)
Dondorp 2010 34/2459 27/2398 100.0 % 1.23 [ 0.74, 2.03 ]
Subtotal (95% CI) 2459 2398 100.0 % 1.23 [ 0.74, 2.03 ]
Total events: 34 (Artesunate), 27 (Quinine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Total (95% CI) 2459 2398 100.0 % 1.23 [ 0.74, 2.03 ]
Total events: 34 (Artesunate), 27 (Quinine)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Artesunate vs quinine, Outcome 6 Coma recovery time (hours).
Review: Artesunate versus quinine for treating severe malaria
Comparison: 1 Artesunate vs quinine
Outcome: 6 Coma recovery time (hours)
Study or subgroup Artesunate Quinine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Anh 1989 19 45.17 (30.29) 22 53.6 (25.87) 51.5 % -8.43 [ -25.82, 8.96 ]
Anh 1995 99 71.3 (81) 91 58 (49) 48.5 % 13.30 [ -5.57, 32.17 ]
Total (95% CI) 118 113 100.0 % 2.11 [ -19.17, 23.40 ]
Heterogeneity: Tau?? = 150.41; Chi?? = 2.76, df = 1 (P = 0.10); I?? =64%
Test for overall effect: Z = 0.19 (P = 0.85)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Artesunate vs quinine, Outcome 7 Time to hospital discharge (days).
Review: Artesunate versus quinine for treating severe malaria
Comparison: 1 Artesunate vs quinine
Outcome: 7 Time to hospital discharge (days)
Study or subgroup Artesunate Quinine
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Newton 2003 59 5.1 (3.14) 54 5 (4.5) 0.10 [ -1.34, 1.54 ]
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Analysis 1.8. Comparison 1 Artesunate vs quinine, Outcome 8 Fever clearance time (hours).
Review: Artesunate versus quinine for treating severe malaria
Comparison: 1 Artesunate vs quinine
Outcome: 8 Fever clearance time (hours)
Study or subgroup Artesunate Quinine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Anh 1995 (1) 99 67.36 (41.4) 91 63.3 (46.5) 35.5 % 4.06 [ -8.50, 16.62 ]
Eltahir 2010 (2) 33 16.2 (8.9) 33 18.2 (10.5) 56.7 % -2.00 [ -6.70, 2.70 ]
Hien 1992 (3) 31 39 (30) 30 78 (102) 7.8 % -39.00 [ -77.00, -1.00 ]
Total (95% CI) 163 154 100.0 % -2.74 [ -14.07, 8.60 ]
Heterogeneity: Tau?? = 53.26; Chi?? = 4.52, df = 2 (P = 0.10); I?? =56%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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(1) Axillary temperature was recorded every 6 h until 4 consecutive temperatures were < 37.5 ??C
(2) Vital signs were monitored every 15 mins for the first hour, then every 2 hours until 24 hours then every 6 hours until the axillary temp first dropped below 37.5
and remained below
for 24 hours.
(3) The axillary temperature was measured at 3 hour intervals until ”fever clearance”
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Analysis 1.9. Comparison 1 Artesunate vs quinine, Outcome 9 Parasite clearance time (hours).
Review: Artesunate versus quinine for treating severe malaria
Comparison: 1 Artesunate vs quinine
Outcome: 9 Parasite clearance time (hours)
Study or subgroup Artesunate Quinine
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Time to clear 50% of parasites
Anh 1989 19 7.58 (3.32) 22 15.73 (9.78) 30.0 % -8.15 [ -12.50, -3.80 ]
Anh 1995 99 10.64 (8.24) 91 16.12 (14.25) 37.5 % -5.48 [ -8.83, -2.13 ]
Hien 1992 31 5.4 (3.2) 30 16.6 (10.7) 32.5 % -11.20 [ -15.19, -7.21 ]
Subtotal (95% CI) 149 143 100.0 % -8.14 [ -11.55, -4.73 ]
Heterogeneity: Tau?? = 5.18; Chi?? = 4.65, df = 2 (P = 0.10); I?? =57%
Test for overall effect: Z = 4.68 (P < 0.00001)
2 Time to clear 90% of parasites
Hien 1992 31 16 (7.7) 30 34.5 (13.8) 100.0 % -18.50 [ -24.13, -12.87 ]
Subtotal (95% CI) 31 30 100.0 % -18.50 [ -24.13, -12.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.44 (P < 0.00001)
3 Time to clear 95% of parasites
Anh 1989 19 20.82 (7.81) 22 36.8 (14.14) 46.0 % -15.98 [ -22.85, -9.11 ]
Anh 1995 99 20.15 (11.4) 91 26.32 (17.52) 54.0 % -6.17 [ -10.41, -1.93 ]
Subtotal (95% CI) 118 113 100.0 % -10.69 [ -20.27, -1.10 ]
Heterogeneity: Tau?? = 39.63; Chi?? = 5.67, df = 1 (P = 0.02); I?? =82%
Test for overall effect: Z = 2.19 (P = 0.029)
4 Time to clear all parasites
Anh 1995 99 38.15 (21) 91 41.55 (23.8) 24.3 % -3.40 [ -9.80, 3.00 ]
Eltahir 2010 33 19.7 (7.1) 33 20.8 (9.2) 26.6 % -1.10 [ -5.06, 2.86 ]
Hien 1992 31 28.1 (11.2) 30 51.2 (23.2) 21.1 % -23.10 [ -32.29, -13.91 ]
Newton 2003 54 62.5 (4.69) 48 76 (2.96) 28.1 % -13.50 [ -15.01, -11.99 ]
Subtotal (95% CI) 217 202 100.0 % -9.77 [ -18.11, -1.44 ]
Heterogeneity: Tau?? = 63.86; Chi?? = 45.29, df = 3 (P<0.00001); I?? =93%
Test for overall effect: Z = 2.30 (P = 0.022)
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Analysis 1.10. Comparison 1 Artesunate vs quinine, Outcome 10 Hypoglycaemia episodes: by age of
participants.
Review: Artesunate versus quinine for treating severe malaria
Comparison: 1 Artesunate vs quinine
Outcome: 10 Hypoglycaemia episodes: by age of participants
Study or subgroup Artesunate Quinine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults (> 15/16 years)
Dondorp 2005 6/633 17/626 14.1 % 0.35 [ 0.14, 0.88 ]
Newton 2003 6/59 15/54 13.0 % 0.37 [ 0.15, 0.88 ]
Subtotal (95% CI) 692 680 27.1 % 0.36 [ 0.19, 0.68 ]
Total events: 12 (Artesunate), 32 (Quinine)
Heterogeneity: Chi?? = 0.01, df = 1 (P = 0.94); I?? =0.0%
Test for overall effect: Z = 3.17 (P = 0.0015)
2 Children (Age < 15 years)
Cao 1997 6/37 9/35 7.7 % 0.63 [ 0.25, 1.59 ]
Dondorp 2005 0/97 2/105 2.0 % 0.22 [ 0.01, 4.45 ]
Dondorp 2010 48/2712 75/2713 62.0 % 0.64 [ 0.45, 0.92 ]
Eltahir 2010 0/33 1/33 1.2 % 0.33 [ 0.01, 7.90 ]
Subtotal (95% CI) 2879 2886 72.9 % 0.62 [ 0.45, 0.87 ]
Total events: 54 (Artesunate), 87 (Quinine)
Heterogeneity: Chi?? = 0.64, df = 3 (P = 0.89); I?? =0.0%
Test for overall effect: Z = 2.81 (P = 0.0049)
Total (95% CI) 3571 3566 100.0 % 0.55 [ 0.41, 0.74 ]
Total events: 66 (Artesunate), 119 (Quinine)
Heterogeneity: Chi?? = 3.00, df = 5 (P = 0.70); I?? =0.0%
Test for overall effect: Z = 4.02 (P = 0.000059)
Test for subgroup differences: Chi?? = 2.30, df = 1 (P = 0.13), I?? =57%
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Analysis 1.11. Comparison 1 Artesunate vs quinine, Outcome 11 Hypoglycaemia episodes: by method of
monitoring.
Review: Artesunate versus quinine for treating severe malaria
Comparison: 1 Artesunate vs quinine
Outcome: 11 Hypoglycaemia episodes: by method of monitoring
Study or subgroup Artesunate Quinine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Routine monitoring
Cao 1997 6/37 9/35 7.7 % 0.63 [ 0.25, 1.59 ]
Eltahir 2010 0/33 1/33 1.2 % 0.33 [ 0.01, 7.90 ]
Newton 2003 6/59 15/54 13.0 % 0.37 [ 0.15, 0.88 ]
Subtotal (95% CI) 129 122 21.9 % 0.46 [ 0.25, 0.85 ]
Total events: 12 (Artesunate), 25 (Quinine)
Heterogeneity: Chi?? = 0.75, df = 2 (P = 0.69); I?? =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
2 Clinical monitoring
Dondorp 2005 6/730 19/731 15.8 % 0.32 [ 0.13, 0.79 ]
Subtotal (95% CI) 730 731 15.8 % 0.32 [ 0.13, 0.79 ]
Total events: 6 (Artesunate), 19 (Quinine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.47 (P = 0.013)
3 Unclear
Dondorp 2010 48/2712 75/2713 62.3 % 0.64 [ 0.45, 0.92 ]
Subtotal (95% CI) 2712 2713 62.3 % 0.64 [ 0.45, 0.92 ]
Total events: 48 (Artesunate), 75 (Quinine)
Heterogeneity: not applicable
Test for overall effect: Z = 2.44 (P = 0.015)
Total (95% CI) 3571 3566 100.0 % 0.55 [ 0.41, 0.74 ]
Total events: 66 (Artesunate), 119 (Quinine)
Heterogeneity: Chi?? = 3.12, df = 4 (P = 0.54); I?? =0.0%
Test for overall effect: Z = 4.02 (P = 0.000057)
Test for subgroup differences: Chi?? = 2.45, df = 2 (P = 0.29), I?? =18%
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A D D I T I O N A L T A B L E S
Table 1. Search methods: detailed search strategy
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb ISI Web of Science
1 malaria malaria malaria malaria malaria malaria
2 quinine quinine quinine quinine quinine quinine
3 artesunate quinimax quinimax quinimax artesunate artesunate
4 artemisinin* CINCHONA
ALKALOIDS
CINCHONA
ALKALOIDS
CINCHONA-
ALKALOID
artemisinin arsumax
5 3 or 4 2 or 3 or 4 2 or 3 or 4 2 or 3 or 4 3 or 4 3 or 4
6 1 and 2 and 5 artesunate artesunate artesunate 1 and 2 and 5 1 and 2 and 5
7 - arsumax arsumax arsumax - -
8 - 6 or 7 6 or 7 6 or 7 - -
9 - 1 and 5 and 8 1 and 5 and 8 1 and 5 and 8 - -
10 - - limit 9 to human limit 9 to human - -
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Higgins
2008); upper case: MeSH or EMTREE heading; lower case: free text term.
Table 2. Definitions of outcome measures used in the review
Trial Death Neurolog-
ical sequelae
at discharge
Coma recov-
ery time
Time to dis-
charge
Fever clear-
ance time
Parasite
clearance
time
Hypogly-
caemia
Adverse ef-
fects
Anh 1989 Death Not reported Mean value
(h) reported
but not de-
fined
Not reported Not reported Mean value
(h) reported
but not
defined. Par-
asite counts
every 8 h un-
til 2 consecu-
tive slides
were negative
and then ev-
ery 24 h
Not reported Not reported
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Table 2. Definitions of outcome measures used in the review (Continued)
Anh 1995 Death Not reported Mean value
(h). Defined
as time until
con-
sciousness re-
gained. Glas-
gow
Coma Scale
measured ev-
ery 12 h until
regained con-
sciousness
Not reported Mean value
(h)
reported but
not defined.
Axillary tem-
perature was
recorded ev-
ery 6 h un-
til 4 consec-
utive temper-
atures were <
37.5 °C
Mean value
(h) reported
but not
defined. Par-
asite count
measured ev-
ery 6 h until
3 consecutive
blood smears
were negative
Not reported Not reported
Cao 1997 Death Number
survived with
neurological
sequelae.
Case defi-
nition for
neurological
sequelae:
abnormal
neurological
signs and/or
symptoms
at time of
discharge
from hospital
that were not
present be-
fore onset of
the episode
of malaria as
reported by
the child’s
parents. All
children
had a full
neurological
examination
on admis-
sion and at
discharge
from hospital
(personal
communi-
cation from
author)
Median value
(h) reported.
Defined
as time (h)
for Blantyre
Coma Score
to become 5/
5. Coma
score assessed
every 4 h (or
more
frequently if
crit-
ically ill) for
the first 24 h,
and then ev-
ery 6 h until
discharge
Median value
(d) reported
Median value
(h) reported.
De-
fined as time
until temper-
ature
first dropped
to 37.5 °C
or below and
remained be-
low this level
for at least
24 h. Axil-
lary tempera-
ture mea-
sured every 4
h (or more
frequently if
crit-
ically ill) for
the first 24 h,
and then ev-
ery 6 h until
discharge
Median value
(h) reported
but not
defined. Par-
asite count
measured ev-
ery
4 h (or more
frequently if
crit-
ically ill) for
the first 24 h,
and then ev-
ery 6 h un-
til discharge.
Once 2 suc-
ces-
sive periph-
eral blood
films had re-
vealed no P.
fal-
ciparum, no
further blood
film
wasmade un-
less indicated
clinically
Blood
glucose < 2.2
mmol/
L. Blood glu-
cose mea-
sured every 4
h for first 24
h and then
every 6 h un-
til discharge
from hospi-
tal if indi-
cated (coma,
prostration,
jaundice, or
> 1 compli-
cation - per-
sonal com-
munication
from author)
Acute re-
nal failure re-
quiring dial-
ysis, shock,
con-
vulsions, de-
terioration of
coma score,
gastrointesti-
nal bleeding,
anaemia re-
quiring
blood trans-
fusion, chest
in-
fection, uri-
nary tract in-
fection, other
infections,
derangement
of biochemi-
cal markers
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Table 2. Definitions of outcome measures used in the review (Continued)
Dondorp
2005
Death Neu-
rological se-
quelae at dis-
charge from
hospital
Not reported Median value
(d) reported
Not reported Not reported Blood
glucose < 2.2
mmol/
L. Blood glu-
cose checked
in all patients
on admission
and then
monitored
on clinical in-
dication
Not reported
Dondorp
2010
Death Severe neuro-
logical com-
plications
(initially as-
sessed at dis-
charge from
hospital but
the protocol
was changed
after 11% of
patients
had been en-
rolled, so that
children who
had not fully
recovered at
discharge
were assessed
28 days after
enrollment)
Not reported Median value
(d) reported
Not reported Not reported Not reported Not reported
Eltahir 2010 Death Not reported Mean value
measured
from admin-
istration
of first anti-
malarial until
the Glasgow
coma
score reached
15. Vi-
tal signs and
coma scale
were mon-
itored every
15 mins for
Not reported Mean value
measured
from admin-
istration
of first anti-
malarial un-
til the axillary
temp first
dropped be-
low 37.5 and
remained be-
low for 24
hours
Mean value
measured
from admin-
istration of
the first anti-
malarial un-
til the first of
two sequen-
tial negative
blood films.
Blood films
were taken
every 4 hours
Blood
glucose lev-
els were mea-
sured every 6
hours.
Not reported
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Table 2. Definitions of outcome measures used in the review (Continued)
the first hour,
then every
2 hours until
24 ours then
every 6 hours
Hien 1992 Death Not reported Mean,
median, and
mode val-
ues reported
in hours. De-
fined as time
to regain full
conscious-
ness (Glas-
gow Coma
Scale of 15/
15). Glasgow
Coma Scale
measured at
3-h intervals
until full re-
covery
of conscious-
ness, and at
6-h intervals
thereafter
Not reported Mean value
(h) reported.
Defined as
time (h) until
“fever clear-
ance”. The
axillary tem-
perature was
measured at
3-h intervals
until
“fever clear-
ance”, and at
6-h intervals
thereafter
Mean value
(h) reported
but not
defined. Par-
asite counts
per-
formed every
4 h for 12 h,
then every 6
h until 3 con-
secutive films
were negative
Not reported None
reported
Newton
2003
Death Not reported Median value
(h) reported.
Defined
as time to
reach a Glas-
gow Coma
Scale of 15 in
those partici-
pants with a
score < 11/
15 on admis-
sion.
Glasgow
Coma Scale
measured ev-
ery 15 min
for first h, at
2 h, and then
every 2 h un-
til 12 h, ev-
ery 4 h from
Not reported Median value
(h) reported.
Defined as
time until the
axillary tem-
perature first
dropped be-
low
37.5 °C and
remained be-
low that level
for 24 h. Ax-
illary temper-
ature
measured ev-
ery 15 min
for the first h,
at 2 h, and
then every 2
h until 12
Median value
(h) reported.
De-
fined as time
to a 50% re-
duction in
parasite den-
sity. Parasite
counts were
measured at
0, 1, 2, 4, 6,
8, 10, 12, 16,
20, and 24 h,
and then ev-
ery 6 h until
6 h after para-
site clearance
Plasma glu-
cose less than
or equal to
2.2 mmol/L.
Plasma
glucose mea-
sured at 0, 4,
8, 12, 16, 20,
and 24 h and
then every 6
h
Seizures,
bleeding and
sep-
sis after ad-
mission, pul-
monary
oedema, olig-
uria, time in
intensive care
unit
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Table 2. Definitions of outcome measures used in the review (Continued)
12 to 24 h,
and every 6
h from 24
h until the
score reached
15
h, every 4 h
from12 to24
h, and every
6 h from 24
h until fever
cleared
Table 3. Time-to-event data: medians, ranges, and modes
Outcome Trial Artesunate Quinine Comparative results re-
ported in article
Coma recovery time (h):
median (range), number
Hien 1992 35 (5 to 453); mode = 17;
mean = 68.9
48 (7 to 144), mode = 43;
mean = 58.1
’Not significantly different’.
Cao 1997 42 (4 to 228), n = 10 31 (4 to 66), n = 2 -
Newton 2003 17 (1 to 125), n = 16 18 (1 to 188), n = 16 ’P = 0.6’
Eltahir 2010 mean = 8.1 (SD not given),
n = 4
mean = 9.1, (SD not given)
, n = 5
’P=0.4’
Time to localise pain (h)
: median (IQR), number
Dondorp 2010 12 (6 to 24), n = 698 12 (6 to 24), n = 726 ’Hazard Ratio 0·87 (0·78-
0·98), P = 0.0093’
Time to speak (h/days):
median (IQR), number
Dondorp 2005 1 day (0.2 to 0.35), n = 730 1 day (0.2 to 0.21), n = 731 ’P = 0.73’
Dondorp 2010 20 hrs (8 to 42), n = 664 18 hrs (11 to 36), n = 695 ’Hazard Ratio 0·88 (0·79-
0·99), P = 0.016’
Time to hospi-
tal discharge (d): median
(range/IQR), number
Cao 1997 8 (5 to 20), n = 33 8 (5 to 24), n = 29 ’P = 0.99’
Dondorp 2005 5 (0 to 54), n = 623 5 (0 to 45), n = 567 ’P = 0.20’
Dondorp 2010 3 (IQR 2 to 5), n = 2478 3 (IQR 2 to 5) n = 2412 ’P = 0.059’
Fever
clearance time (until first
below 37.5 °C) (h): me-
dian (range), number
Cao 1997 4 (4 to 198), n = 35 8 (0 to 96), n = 35 ’P = 0.17’
Newton 2003 11 (1 to 83), n = 42 13 (1 to 184), n = 42 ’P = 0.2’
Fever clearance time (un-
til remains below 37.5
°C for 24 h) (h): median
(range), number
Cao 1997 84 (4 to 198), n = 35 81 (0 to 246), n = 30 ’P = 0.62’
Newton 2003 41 (3 to 138), n = 32 65 (12 to 383), n = 27 ’P = 0.2’
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Table 3. Time-to-event data: medians, ranges, and modes (Continued)
Time to parasite clear-
ance of 50% (h): median
(range), number
Cao 1997 5.7 (2.0 to 15.3), n = 35 13.2 (2.4 to 103.0), n = 32 ’P < 0.0001’
Newton 2003 9.1 (0.3 to 37.2), n = 56 8.0 (0.2 to 46.0), n = 49 ’P = 0.3’
Time to parasite clear-
ance of 90% (h): median
(range), number
Cao 1997 12.0 (3.7 to 35.0), n=35 27.7 (7.5 to 107.0), n=32 ’P < 0.0001’
Newton 2003 20.5 (2.8 to 50.11), n=54 24.7 (0.9 to 67.7), n=48 ’P = 0.08’
Time to parasite clear-
ance of 100% (h): me-
dian (range), number
Cao 1997 36.0 (16.0 to126.0), n=34 84.0 (12.0 to 240.0), n=32 ’P < 0.0001’
Table 4. Adverse event reporting
Study ID Additional comments on adverse events
Anh 1989 No comment on adverse events
Anh 1995 No comment on adverse events
Cao 1997 ’All 3 drug regimens were well tolerated, and no patient had to discontinue treatment because of adverse effects.’
This study also conducted some cardiac monitoring on a non-randomised subset of patients and does not report
any significant differences between groups
Dondorp 2005 ’With the exception of hypoglycaemia there were no serious adverse effects that could be attributed to either
treatment.’
Dondorp 2010 ’We detected no severe adverse effects that could be attributed directly to drug toxicity. Although one patient
treated with artesunate developed a mild urticarial rash, no severe type 1 hypersensitivity reactions were recorded.’
Eltahir 2010 ’Following quinine infusion, 12 patients developed tinnitus and one hypoglycaemia. Abdominal pain and nausea
were observed in three and four patients in artesunate and quinine groups, respectively.’
Hien 1992 No comment on adverse events
Newton 2003 ’Patients treated with quinine consistently developed cinchonism and had a significantly higher frequency of
hypoglycemia. One patient had a probable adverse reaction to artesunate. This patient presented with parasitaemia
of 31%, a plasma lactate level of 14.5 mmol/L, and a serum bilirubin level of 23 mg/dL and developed a widespread
erythematous urticarial rash 17 h after treatment with intravenous artesunate was initiated.’
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Table 5. Summary of cost-effectiveness studies
Lubell 2009 Lubell 2011
Location(s) Asia Sub-Saharan Africa
Population Mostly adults (86%) Children
Type of analysis Cost-effectiveness Cost-effectiveness
Perspective taken Provider Provider
Main cost categories Drug cost (but not administration costs)
Inpatient care cost
Drugs
Fluids
Laboratories
Hotel
Currency USD USD
Price year 2008 2009
Sensitivity analysis? Yes Yes
Time horizon Immediate Immediate
Total cost per treatment episode arte-
sunate vs. quinine
$43.0 vs. $32.4 $66.5 vs. $63.5
Number needed to treat 13 41
Incremental cost per death averted $135.6 $123
Incremental cost per DALY averted Not calculated $3.8
WH A T ’ S N E W
Last assessed as up-to-date: 31 January 2011.
Date Event Description
10 May 2012 New search has been performed updated with ecomonic evaluation
10 May 2012 New citation required but conclusions have not changed Economic evaluation conducted by new author (R. Isba)
and added to the review
52Artesunate versus quinine for treating severe malaria (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
H I S T O R Y
Protocol first published: Issue 2, 2006
Review first published: Issue 4, 2007
Date Event Description
12 April 2011 Amended Dates corrected (review assessed as up-to-date is 31
January 2011, not 2010 as previously stated)
16 February 2011 New citation required and conclusions have changed Two new trials of artesunate versus quinine in African
children have been added
28 November 2010 New search has been performed Major update. New Search November 2010. David
Sinclair has joined the author team and become con-
tact author, and Katharine Jones has stepped down
from the author team
30 July 2009 New search has been performed New search conducted; no new trials for inclusion.
Contact person changed
5 August 2008 Amended Converted to new review format with minor editing.
C O N T R I B U T I O N S O F A U T H O R S
Katharine Jones and Sarah Donegan assessed the eligibility and methodological quality of trials, extracted and analysed data, and
completed the first published version of the review. David Sinclair replaced Katharine Jones for the 2011 update of this review. David
Lalloo contributed to the design and writing of the review. Rachel Isba designed and conducted the economic commentary.
D E C L A R A T I O N S O F I N T E R E S T
Dr David Lalloo was part of the data and safety monitoring committee for the two Dondorp trials. This committee is independent,
does not run or gain anything from the trial, and has a main role of protecting participants.
S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
• University of Liverpool, UK.
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External sources
• Department for International Development (DFID), UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
2007, Issue 4 (first review version): We removed the requirement for all participants to fulfil the WHO definition for severe malaria
(Gilles 2000) in view of the large number of participants this would have excluded from the review as the largest included trial used a
clinical case definition.
We changed the intervention from “parenteral artesunate” to “intravenous, intramuscular, or rectal artesunate” to clarify that trials
using artesunate suppositories would be included in the review.
We subgrouped “neurological sequelae” into “neurological sequelae at discharge” and “neurological sequelae at day 28”.
We added a number of sensitivity analyses post-hoc after noting significant variation in study design across trials.
We presented data for hypoglycaemia in a forest plot rather than a table as stated in the protocol to reflect the clinical importance of
this outcome.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antimalarials [administration & dosage; ∗therapeutic use]; Artemisinins [administration & dosage; ∗therapeutic use]; Injections,
Intramuscular; Injections, Intravenous; Malaria [∗drug therapy; mortality]; Quinine [administration & dosage; ∗therapeutic use];
Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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